Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Recurrence 3Pancreatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Uterine Cervical Neoplasms 1Tracheal Diseases 1Smoking Cessation 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Peritoneal Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphedema 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × Combined Modality Therapy × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06993506 2025-05-29

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
500 enrolled

Neoplasm Metastasis, Recurrence

NCT01889420 2015-07-31

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

New Mexico Cancer Research Alliance

Phase 1 Terminated
1 enrolled 3 charts
Plasma cell

Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡